Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
Nodify Lung testing is a new tool to help physicians determine the risk of malignancy of lung nodules. Learn more about how Nodify testing works https://qoo.ly/34ux3c. #PulmCC #LungCancer #NSCLC #LungNodule
Make lung cancer screening available to all using a simple blood test. If you think its a good idea (& why wouldn't you), help @OncimmuneECDT make it happen & sign the petition here >>> http://chng.it/cD2TVnmX
Wonderful! Fantastic article on @OncimmuneECDT & their revolutionary EarlyCDT-Lung test. Read in full here >
Simple blood saving lives by detecting lung cancer before symptoms
Rebecca Allison, 69, and Shirley Dolan, 63, were both recipients of a revolutionary blood test - called the EarlyCDT-Lung test - that detected their ...
ow.ly
Lung cancer a primary cause of death can be detected much earlier with a simple blood test resulting in better outcomes at lower cost
#healthliteracy #healtheducation #hcpsupport #healthtechnology #patienteducation #healthoutcomes #cancer #healthcare
https://dailym.ai/2InQN10
Biodesix strengthens lung nodule testing with Nodify CDT Test: Biodesix Inc. a leader in lung cancer diagnostics is extending its bloodbased testing portfolio with the release of the Nodify CDTTM test designed to help physicians identify patients The…
Biodesix strengthens lung nodule testing with Nodify CDT Test
From BioPortfolio: Biodesix, Inc. a leader in lung cancer diagnostics, is extending its blood-based testing portfolio with the release of the Nodify C...
bioportfol.io
$ONC #Oncimmune Holdings Oncimmune (ONC LN): Oncimmune has moved firmly into commercialisation phase via the launch of its EarlyCDT Lung test by its exclusive US partner Biodesix, as a rule-in test to identify patients with lung nodules… http://dlvr.it/RRDLbV #equity #stocks
Congratulations to BIVDA member @OncimmuneECDT for this splash in the @DailyMailUK on their new diagnostics test. #diagnostics #lungcancer #testing
Simple blood saving lives by detecting lung cancer before symptoms
Rebecca Allison, 69, and Shirley Dolan, 63, were both recipients of a revolutionary blood test - called the EarlyCDT-Lung test - that detected their ...
www.dailymail.co.uk
We are delighted with the launch of Nodify CDT by our exclusive US partner @BiodesixInc for the identification of lung nodules #lungcancer #extratime
Biodesix Strengthens Lung Nodule Testing Strategy with the Nodify CDT™ Test
Biodesix, Inc. a leader in lung cancer diagnostics, is extending its blood-based testing portfolio with the release of the Nodify CDTTM test, designed
dlvr.it
Gallery
